Endonovo Therapeutics, Inc.

OTCPK:ENDV Stock Report

Market Cap: US$180.8k

Endonovo Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Alan Collier

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure14.3yrs
CEO ownershipn/a
Management average tenure9.3yrs
Board average tenure7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Alan Collier's remuneration changed compared to Endonovo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$9m

Dec 31 2022US$850kUS$300k

-US$18m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$300kUS$300k

-US$3m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$300kUS$300k

-US$396k

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$11m

Dec 31 2019US$315kUS$300k

-US$17m

Compensation vs Market: Insufficient data to establish whether Alan's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Alan's compensation with company performance.

CEO

Alan Collier (60 yo)

14.3yrs
Tenure
US$850,000
Compensation

Mr. Alan Brian Collier has been the Chief Executive Officer at Endonovo Therapeutics, Inc. since March 2012 and serves as its Chairman and served as its Secretary since March 2012. He served as Interim Chi...

Leadership Team

NamePositionTenureCompensationOwnership
Alan Collier
Chairman & CEO14.3yrsUS$850.00kno data
Don Calabria
Vice President of Operations14.3yrsno datano data
Garry Kann
Head of Corporate Development4.3yrsno datano data
Ira Weisberg
President & Chief Commercial Officer of Medical Division3.6yrsno datano data
9.3yrs
Average Tenure

Experienced Management: ENDV's management team is seasoned and experienced (9.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alan Collier
Chairman & CEO14.3yrsUS$850.00kno data
Roc McCarthy
Member of Scientific Advisory Board7.1yrsno datano data
Steven Levin
Member of Scientific Advisory Board7yrsno datano data
Peter Novak
Member of Scientific Advisory Board6.9yrsno datano data
Geoffrey Abrams
Member of Scientific Advisory Board6.8yrsno datano data
Samir Awad
Member of Scientific Advisory Board6.8yrsno datano data
Mykol Larvie
Member of Scientific Advisory Boardno datano datano data
Nathan Guerette
Member of Scientific Advisory Boardno datano datano data
Ashling O'Connor
Member of Scientific Advisory Boardno datano datano data
7.0yrs
Average Tenure

Experienced Board: ENDV's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 00:56
End of Day Share Price 2026/06/26 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Endonovo Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.